Autism One is an International conference in which vanguard researchers, novelty ideas and products geared toward those with autism hit the spotlight. The RoC had the privilege not only of having a booth but also of sitting on a panel with experts and doctors and furthermore of presenting some of the preliminary results of our Observational Research Registry (ORR) with Johns Hopkins University (JHU).
There were a plethora of vendors present. They ranged from raw Camel's Milk purveyors, light therapy providers, nutritional supplements, cannabis and hemp based product companies and non-profit foundations. In fact, two of the companies we support were present: Elixinol and Charlotte's Web.
At our RoC booth, we were able to hear touching stories and educate parents about options. Every day was a new experience and we heard plenty of touching stories from parents with children on the spectrum. One mother even related that after cannabinoid therapy her daughter had begun to utter words more clearly. We talked to quite a few parents who desired more information pertaining to cannabis and autism and we were able to provide guidance. Furthermore, our new employees Sara and Kelly gained valuable experience. They both did outstanding work offering guidance and information to those who were seeking both.
There were several lectures regarding cannabis and autism. There is a laboratory in California who is currently seeing success with small doses of THC-A added to current regimens for those with autism and other issues. It is important to note that the THC-A (which is their approach and area of study) is an optional addition (for some) to a wider regimen with cannabis, notably one that includes extracts rich in CBD. Another doctor in Florida has patented a CBD isolate cream, which, when rubbed on the back of the neck, at the hairline, is supposed to target "free nerve endings," which, apparently, are located directly on the skin and affect the brain. This novel method allegedly bypasses the bloodstream while still affecting the central nervous system and brain. Quite interesting.
As well, the RoC was able to present some preliminary results and data regarding those who are on the autism spectrum from our ORR with JHU. It seems that in general those with autism who also use cannabis see better results in a number of measures, including: medical services usage (Outpatient, ER and Hospital Admissions), general validated measures for quality of life (physical measures, psychological measures, social relationships, environment, and general quality of life), sleep habits, anxiety, and depression. Even though there is some promising preliminary data evidence; it is important to remember that this is, under no circumstances conclusive. This longitudinal project is far from over.
Lastly, the RoC sat on a panel with industry experts, including doctors and even the CW CEO, Joel Stanley. The general consensus is that cannabis is pushing medicine in general, and more specifically, medicine pertaining to autism towards individualized therapy. Different applications were discussed and options abound. There are many options for children, and the options available to an individual depend on what state you reside in. Furthermore, although the day is not yet here, genetic testing is pushing to breakthroughs in matching individuals and their unique genetic codes with specific ratios/strains/treatment pathways. We live in an exciting time where cannabis research is coming to the forefront and intersection of medical research in many areas. Autism One is a conference that is an example of the importance of research in general and especially cannabis research, in the context of many illnesses.